Oliver Benes, MD
Addiction Medicine · Covington, KYNPI 1972742963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AbbVie at 26.7% of the total. Reporting peaked in 2019 at $897 and has fallen 63.1% since, to $332 in 2025.
Across 178 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$775
- Johnson & Johnson$157
- Indivior Inc.$149
- Amgen$148
- Alkermes, Inc.$146
- Supernus Pharmaceuticals, Inc.$118
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,903100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $775 |
| Johnson & Johnson | 13 | $157 |
| Indivior Inc. | 7 | $149 |
| Amgen | 10 | $148 |
| Alkermes, Inc. | 8 | $146 |
| Supernus Pharmaceuticals, Inc. | 5 | $118 |
| Axsome Therapeutics, Inc. | 4 | $118 |
| Pfizer | 8 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $104 |
| GSK | 7 | $103 |
| Braeburn Inc. | 7 | $100 |
| Novo Nordisk | 7 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Boehringer Ingelheim | 4 | $77 |
| Avanir Pharmaceuticals, Inc. | 2 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Lilly USA, LLC | 4 | $55 |
| Astellas Pharma US Inc | 2 | $44 |
| AstraZeneca | 3 | $39 |
| USWM, LLC | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $27 |
| Merck | 2 | $25 |
| Genentech USA, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Orexo US, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Novartis | 1 | $11 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
| Hologic Sales And Service, LLC | 1 | $9 |
How this compares
$2,903 in reported general payments places this provider in the 80th percentile of 40 addiction medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VivitrolNaltrexone Microspheres | 19 | $30,659 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 219 | $12,517 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 30 | $7,577 |
| Amitriptyline Hcl | 12 | $720 |
| Doxepin Hcl | 26 | $586 |
| Topiramate | 18 | $551 |
| Tamsulosin Hcl | 14 | $431 |
| Ondansetron OdtOndansetron | 15 | $392 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $344 |
| Hydroxyzine Hcl | 14 | $188 |
| Bupropion XlBupropion Hcl | 11 | $179 |
| Fluticasone Propionate | 17 | $159 |
| Nortriptyline Hcl | 16 | $120 |
| Duloxetine Hcl | 16 | $107 |
| Trazodone Hcl | 16 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Vivitrol | $146 | $30,65919 claims |
| Orexo US, Inc.Zubsolv | $14 | $7,57730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 40 addiction medicine providers in Kentucky.
Other addiction medicine in Covington
- Teresa KoellerCovington$3K
- Mina KalfasCovington$2K
- Kathleen YangCovington$245
- Anastasia JandesLexington$55K
- Rallie McAllisterLexington$17K
- Michael KindredLexington$13K
- Asad IsmailLouisville$10K
- Guy LernerElizabethtown$10K
- Joseph KoenigsmarkShepherdsville$3K
- Barry HardisonCentral City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.